Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. [electronic resource]
Producer: 20100308Description: 38-47 p. digitalISSN:- 1474-5488
- Aged
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Austria
- Camptothecin -- adverse effects
- Cetuximab
- Chemotherapy, Adjuvant
- Colorectal Neoplasms -- pathology
- ErbB Receptors -- analysis
- Female
- Fluorouracil -- adverse effects
- Germany
- Hepatectomy
- Humans
- Leucovorin -- adverse effects
- Linear Models
- Liver Neoplasms -- chemistry
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Mutation
- Neoadjuvant Therapy
- Odds Ratio
- Organoplatinum Compounds -- adverse effects
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins B-raf -- genetics
- Proto-Oncogene Proteins p21(ras)
- Retrospective Studies
- Risk Assessment
- Time Factors
- Tomography, Spiral Computed
- Treatment Outcome
- ras Proteins -- genetics
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.